SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that management will participate in a fireside chat at the BTIG Ophthalmology Day on Monday, November 27, 2023, at 3:00 p.m. ET.
The Belite management team will be participating in one-on-one meetings at the event. Investors interested in meeting with Belite at the conference should contact their BTIG representative.
About Belite Bio
About Belite Bio Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease and geographic atrophy in advanced dry age-related macular degeneration, in addition to specific metabolic diseases. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at www.belitebio.com.
Media and Investor Relations Contacts:
Jennifer Wu
This email address is being protected from spambots. You need JavaScript enabled to view it.
Julie Fallon
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$48.50 |
Daily Change: | -0.13 -0.27 |
Daily Volume: | 159,120 |
Market Cap: | US$1.440B |
June 12, 2024 March 22, 2024 March 11, 2024 November 13, 2023 |
UGE International develops, owns, and operates commercial and community solar projects in the United States and strategic markets abroad. Our distributed energy solutions deliver cheaper, cleaner energy to businesses and consumers...
CLICK TO LEARN MOREDevvStream provides upfront capital for sustainability projects in exchange for carbon credit rights. Through these rights, the company generates and manages carbon credits by utilizing the most technologically advanced...
CLICK TO LEARN MORECOPYRIGHT ©2022 GREEN STOCK NEWS